The dilemma of treating young women with generalized epilepsy with sodium valproate and how to get out of it
The dilemma
Despite the introduction of modern antiepileptic drugs (AEDs) such as lamotrigine or topiramate, sodium valproate (VPA) is seen by many as the most effective medication for seizure control in idiopathic generalized epilepsy (IGE). The case vignettes and the great review by Mole et al. 1 in this issue dramatically illustrate the ill effects of withholding VPA for seizure control and the therapeutic benefits of VPA. That is however only one side of the coin. The other side of the coin is that we have learnt in the last 30 years that VPA is the most teratogenic epilepsy drug on the market with an overall risk of 11% for major congenital malformations.
2 VPA monotherapy is associated with significantly increased risks for six specific malformations including spina bifida 12.7-fold increased risk for spina bifida. 3 Although alarming, this is not new. Preliminary case reports were published as early in the mid-1980s. 4 In addition, Meador and colleagues 5 have convincingly shown in recent years that exposure to VPA during early pregnancy causes long-lasting intelligence deficits in the offspring. 5 The effect was dose dependent, and the impact of the effect appeared greater in verbal than in nonverbal abilities. 5 Given these risks, physicians are justifiably reluctant to recommend VPA in young women with generalized epilepsy unless contraceptive measures are taken. Yet, the merit of the opinion piece by Mole et al., 1 is that it they reminded us that indiscriminately withholding VPA in young women with generalized epilepsy may not be the best solution, either. How can we get out of this dilemma?
Ways out of the dilemma
There is general agreement that, if possible, VPA should be avoided in the first trimester of pregnancy due to the risks. 6 If this is not possible, when, for example, prior attempts to lower the dose or to stop VPA altogether have been unsuccessful, women should be warned that stopping or lowering the dose of VPA should not be done without consultation with her physician. Once it has been determined that VPA needs to be continued during pregnancy, the patient must be informed of the relative risks including the general side-effect profile of VPA, particularly weight gain, and counseled appropriately. Counseling about the teratogenic risks of major congenital malformations should include the important information that the vast majority of children will be unaffected. If VPA is needed, it should preferably be given prior to or during pregnancy at daily doses not exceeding 1000 mg. This recommendation is based on evidence suggesting that the teratogenic risk of VPA seems to be higher at daily doses beyond 1000 mg. 7 If 800-1000 mg/day of VPA do not achieve seizure-freedom, it is better to find this out prior to than during pregnancy, if possible. It is reassuring in that respect that pregnancy itself does not seem to substantially affect seizure control. 8 Whether absence or myoclonic seizures and self-limiting, brief tonic-clonic-seizures affect the health and the development of the child in utero, is not well known. However, prolonged seizures and status epilepticus are thought to be a serious threat to both mother and fetus according to a case report. 9 Most physicians seem to prefer to add another suitable AED, if needed for seizure control, and shy away from removing VPA during pregnancy (as any other AED).
As a caveat, it should be noted that the best evidence for the usefulness of any of these treatment options during pregnancy is largely anecdotal as in any patient with refractory generalized epilepsy. Folate supplementation (at least 0.4 mg folic acid/day) is generally recommended during conception and pregnancy although the proper dose and the treatment effect, if any, is not well known. 6 In summary, navigating VPA treatment in women with generalized epilepsy who need it, by protecting from teratogenic risks and yet maintaining or achieving seizure control requires an individualized balance. Mole and colleagues 1 are commended to have reminded us that a one-sided approach to ban sodium valproate from the treatment of women with generalized epilepsy may not always be in the best interest of the patient.
